TY - JOUR
T1 - Pharmacological interventions for stress ulcer prophylaxis in critically ill patients
T2 - a mixed treatment comparison network meta-analysis and a recursive cumulative meta-analysis
AU - Sridharan, Kannan
AU - Sivaramakrishnan, Gowri
AU - Gnanaraj, Jerome
N1 - Publisher Copyright:
© 2017 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2018/1/22
Y1 - 2018/1/22
N2 - Background: Proton pump inhibitors (PPI), histamine-2 receptor antagonists (H2RA), sucralfate and antacids are the commonly administered agents for stress ulcer prophylaxis (SUP) in critically ill patients. The authors of this paper have conducted a network meta-analysis to compare the efficacy of these agents in SUP. Methods: Electronic databases were searched for randomized controlled trials, cohort studies and conference abstracts for studies comparing a SUP agent in critically ill patients to another active SUP agent or placebo. Overt, occult and clinically significant upper gastro-intestinal (UGI) bleeding, all-cause mortality, pneumonia, gastric colonization and ICU length of stay were considered as the outcome measures. A random effects model was used to generate pooled estimates. Results: A total of 53 studies (4258 participants) were included. The pooled estimates were in favor of PPI and sucralfate for the overt UGI bleeding. PPI and H2RA bolus were associated with increased risk of gastric colonization and pneumonia. Conclusions: SUP in critically ill patients was not associated with any benefit with regard to clinically significant bleeding episodes. However, PPI and sucralfate significantly reduces overt UGI bleeding. On the contrary, PPI and H2RA bolus are associated with an increased risk of gastric colonization and pneumonia.
AB - Background: Proton pump inhibitors (PPI), histamine-2 receptor antagonists (H2RA), sucralfate and antacids are the commonly administered agents for stress ulcer prophylaxis (SUP) in critically ill patients. The authors of this paper have conducted a network meta-analysis to compare the efficacy of these agents in SUP. Methods: Electronic databases were searched for randomized controlled trials, cohort studies and conference abstracts for studies comparing a SUP agent in critically ill patients to another active SUP agent or placebo. Overt, occult and clinically significant upper gastro-intestinal (UGI) bleeding, all-cause mortality, pneumonia, gastric colonization and ICU length of stay were considered as the outcome measures. A random effects model was used to generate pooled estimates. Results: A total of 53 studies (4258 participants) were included. The pooled estimates were in favor of PPI and sucralfate for the overt UGI bleeding. PPI and H2RA bolus were associated with increased risk of gastric colonization and pneumonia. Conclusions: SUP in critically ill patients was not associated with any benefit with regard to clinically significant bleeding episodes. However, PPI and sucralfate significantly reduces overt UGI bleeding. On the contrary, PPI and H2RA bolus are associated with an increased risk of gastric colonization and pneumonia.
KW - Proton pump inhibitors
KW - anti-ulcer drugs
KW - gastro-intestinal bleeding
KW - histamine receptor blockers
KW - pneumonia
KW - sucralfate
UR - http://www.scopus.com/inward/record.url?scp=85038856022&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85038856022&partnerID=8YFLogxK
U2 - 10.1080/14656566.2017.1419187
DO - 10.1080/14656566.2017.1419187
M3 - Article
C2 - 29271262
AN - SCOPUS:85038856022
SN - 1465-6566
VL - 19
SP - 151
EP - 158
JO - Expert opinion on pharmacotherapy
JF - Expert opinion on pharmacotherapy
IS - 2
ER -